Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IR-775 is a hydrophobic near-infrared heptamethine cyanine small-molecule dye used primarily as an experimental phototheranostic agent rather than an approved medicine. In the published literature, it functions as a photosensitizer and photothermal transducer for fluorescence imaging, photodynamic therapy, and photothermal therapy, often after encapsulation into liposomes, polymeric nanoparticles, cyclodextrin nanocarriers, or other delivery systems to improve solubility, tumor delivery, and cellular uptake. Upon near-infrared light irradiation, IR-775 generates reactive oxygen species and heat, enabling image-guided tumor ablation in preclinical cancer models; it has also been used as a fluorescent tracer cargo in drug-delivery studies. The available evidence indicates preclinical development only, with no clear evidence from the provided sources of an approved developer-led pharmaceutical product or commercial brand.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IR-775.